Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028
Company to host conference call today at 4:30 pm ET
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; 'Cullinan'), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T cell engager. Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory (r/r) multiple myeloma (MM). Cullinan will develop velinotamig in autoimmune diseases.
'We believe T cell engagers represent the next wave of innovation in autoimmune diseases, and we are excited to build upon our core T cell engager expertise and extensive KOL relationships to develop another potential best-in-class, clinical-stage program. Accumulated data supports BCMA as a promising target in autoimmune diseases, offering a precise and potentially disease-modifying approach by eliminating the entirety of the self-reactive plasma cells that result in certain autoimmune diseases, especially those diseases driven by long-lived plasma cells,' said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics. 'Adding a BCMAxCD3 bispecific T cell engager to our pipeline complements our rapid global clinical development of CLN-978, enabling us to address the needs of more patients across a broader range of autoimmune diseases than with either molecule alone.'
Genrix plans to initiate a Phase 1 study in China by the end of this year in patients with autoimmune diseases. Cullinan intends to use the data generated to accelerate global clinical development of the program. Following the completion of the Genrix Bio Phase 1 study, Cullinan will conduct all further development of velinotamig in autoimmune diseases.
'With our planned Phase 1 study of velinotamig in autoimmune diseases, we will be able to quickly leverage our experience in autoimmune diseases to complete the study in China expeditiously,' said Dr. Liu Zhigang, Chairman, Chief Executive Officer, and Chief Science Officer of Genrix Biopharmaceutical 'Cullinan is a proven leader in developing T cell engagers and we are confident in the company's ability to carry the program forward to address the needs of patients with autoimmune diseases.'
Under the agreement, Cullinan will pay Genrix Bio an upfront license fee of $20 million for exclusive rights to develop and commercialize velinotamig in all disease areas globally outside of Greater China. In the future, Genrix will also be eligible to receive up to $292 million in development and regulatory milestones plus up to an additional $400M in sales-based milestones, as well as tiered royalties from mid-single digits up to the mid- teens on potential ex-Greater China net sales.
Importantly, with refinement of the clinical oncology pipeline, Cullinan reiterates its existing guidance to have cash resources into 2028 based on its current operating plan.
Cullinan Therapeutics Conference Call Information
Cullinan Therapeutics will host a conference call today, June 4, at 4:30 pm ET. Investors, analysts and the general public are invited to listen to a live webcast of the call. A link to join the call and to find related materials will be available under the Events and Presentations section of the Company's investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Velinotamig
Velinotamig is a bispecific antibody that can simultaneously bind to the BCMA and CD3 antigens, redirecting cytotoxic T cells to target BCMA-expressing cells. Velinotamig has high affinity for BCMA and lower affinity for CD3. Affinity for BCMA is two orders of magnitude higher than for CD3, ensuring that the bispecific antibody recruits and activates T cells while minimizing non-specific T cell activation and reducing the toxicity mediated by the CD3 antibody.
Genrix Bio received approval from the National Medical Products Administration (NMPA) in January 2022 to conduct clinical trials for the indication of multiple myeloma. Velinotamig received Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) for the treatment of relapsed and refractory multiple myeloma.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
About Genrix Bio
Genrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. With antibody drug R&D centers in Beijing, Shanghai, and Chongqing, we are committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Our capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Upholding the philosophy of "to deliver affordable and reliable new medicines for patients," we strive to address the clinical needs of a wider population. Learn more about Genrix Bio at https://www.genrixbio.com/#/home.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan's beliefs and expectations regarding the potential benefits of, and plans relating to, the license agreement between Cullinan and Genrix Bio, including anticipated milestone payments under the license agreement, as well as royalties on net sales; the therapeutic potential of velinotamig; the timing of planned clinical development of velinotamig; our expectations regarding our cash resources; and other statements that are not historical facts. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'hope,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'should,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the success of our clinical trials and preclinical studies; risks related to our ability to protect and maintain our intellectual property position; risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption 'Risk Factors' in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.
Contacts:
InvestorsNick Smith+1 401.241.3516nsmith@cullinantx.com
Media Rose Weldon+1 215.801.7644rweldon@cullinantx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
CrowdStrike Unveils Falcon Next-Gen Identity Security, the First Unified Solution to Protect Every Identity Across the Attack Chain
AUSTIN, Texas--(BUSINESS WIRE)-- CrowdStrike (NASDAQ: CRWD) today announced CrowdStrike Falcon® Next-Gen Identity Security, the first unified solution to protect every identity – human, non-human, and AI agent – across the full hybrid identity lifecycle and every environment. Delivered today, without delays or integration complexity through the AI-native CrowdStrike Falcon® platform, the new offering protects identities across on-premises, cloud, SaaS, and workloads, removing security blind spots and replacing fragmented controls. CrowdStrike unifies initial access prevention, modern privileged access management (PAM), identity threat detection and response (ITDR), SaaS identity security, and agentic identity protection to stop identity-driven breaches across domains. 'Organizations need trusted identity security now, not months or years from now. CrowdStrike provides what customers need most in a unified platform: modern identity security by design, without architectural trade-offs and integration debt," said Mike Sentonas, president, CrowdStrike. "Access in today's enterprise is dynamic and unpredictable, with identities spanning users, machines, and AI agents operating across hybrid environments in real time. The Falcon platform was built to manage this complexity, providing the speed, scale, and precision organizations need to stop modern identity attacks.' Identity has become the primary path adversaries take to compromise an organization. Attackers increasingly exploit a broad spectrum of identities that span human users, service accounts (non-human identities), SaaS credentials, and now, autonomous AI agents. Each agent represents a superhuman identity with persistent access to systems, applications, and sensitive data. These non-human agent identities dramatically increase the size and severity of the attack surface: more identities across more environments, more privileges across more workflows, and more opportunity for adversaries to move faster than defenders can respond. Modern adversaries exploit this access to move seamlessly across domains – endpoint, identity, cloud, and SaaS – leaving organizations that rely on traditional IAM and legacy PAM tools exposed to cross-domain attacks. Falcon Next-Gen Identity Security closes the gaps that adversaries exploit with a unified solution that delivers continuous protection across identity types (human, non-human and AI agent), environments, and stages of the identity attack chain. From initial access to lateral movement, CrowdStrike protects human, non-human, and AI agents across hybrid environments, including on-prem, cloud, and SaaS. Powered by CrowdStrike's agentic AI, organizations gain autonomous threat analysis and response that helps them detect, investigate, and stop identity-based attacks in real time, through a single unified platform. Organizations can immediately strengthen their security posture without waiting for promised integrations, or accepting identity capabilities fragmented across multiple platforms that replicate the same complexity and security gaps as multi-vendor solutions. Delivered through a single lightweight sensor and managed from a single console, CrowdStrike gives defenders real-time visibility, dynamic access enforcement, and autonomous response across every identity and every domain. CrowdStrike's Unified Platform for Securing Every Identity Across Hybrid Environments Falcon Next-Gen Identity Security unifies four core capabilities to deliver end-to-end visibility, control, and protection of identities, privileges, and risk across the full attack chain in hybrid identity environments: Initial Access Prevention: Leverages real-time endpoint signals, industry-leading threat intelligence, and AI trained on trillions of events to authenticate trusted identities, dynamically blocking threats before adversaries can gain initial access. Modern Privileged Access Management (PAM): Enforces just-in-time access and eliminates standing privileges. Dynamically adjusts access based on real-time risk to secure sensitive systems across hybrid and multi-cloud environments. Identity Threat Detection and Response (ITDR): Detects and stops identity-based attacks in real time. Uses cross-domain telemetry and agentic AI to triage threats, enforce policy, and block lateral movement and privilege escalation. SaaS Identity Security: Identifies misconfigurations, flags risky behaviors, and governs overprovisioned access – for humans, non-human identities, and AI agents – across cloud-first applications. Delivered through the CrowdStrike Falcon platform, Falcon Next-Gen Identity Security replaces fragmented tools and disconnected workflows. Security teams gain real-time visibility, dynamic enforcement, and autonomous response across every identity and every domain. With rapid deployment and immediate time-to-value, organizations can strengthen their identity security posture today, without waiting for integrations or accepting security gaps. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.
Business Wire
a few seconds ago
- Business Wire
Oblong Reports Q2 2025 Results and Expands $8M TAO Treasury to Power Decentralized AI
DENVER--(BUSINESS WIRE)--Oblong, Inc. (Nasdaq: OBLG) ('Oblong' or the 'Company'), a digital asset treasury company, today announced financial results for the second quarter ended June 30, 2025 ('Q2 2025') and significant progress in its treasury strategy centered on Bittensor's TAO token. With artificial intelligence projected to reach a $1.2 trillion market by 2030, Oblong is pioneering a treasury strategy that leverages TAO to drive financial returns and decentralized AI innovation. Bittensor's network, powered by over 500 active nodes, incentivizes collaborative AI development, positioning TAO as a critical asset for forward-thinking companies. 'Oblong's $8.0 million investment in 21,613 TAO tokens, all staked in the Bittensor network, generates revenue while strengthening our role in the decentralized AI ecosystem,' said Pete Holst, CEO of Oblong. 'Our strategy positions us at the forefront of AI-driven finance, delivering value through strategic treasury management.' Q2 2025 Financial and Strategic Highlights Strong Financial Position: As of June 30, 2025, Oblong held $10.8 million in cash and cash equivalents, $1.7 million in TAO holdings, and zero debt. TAO Treasury Expansion: Invested $1.7 million in Q2 2025 to acquire 5,025 TAO tokens, followed by $6.35 million post-Q2 to purchase 16,506 additional tokens, totaling 21,613 tokens, all staked to generate revenue and support Bittensor's decentralized AI network. Capital Raising: Secured $6.9 million from a private placement and $1.3 million from common warrant exercises in Q2 2025, with an additional $0.9 million from warrant exercises post-Q2. Revenue and Loss: Generated $0.6 million in revenue, consistent with Q2 2024, with a net loss of $0.6 million, improved from $1.0 million in Q2 2024. Adjusted EBITDA loss was $0.7 million, improved from $1.0 million in Q2 2024 (see 'Non-GAAP Financial Information' below). Strategic Outlook: Committed to evaluating weekly TAO purchases and exploring partnerships to develop AI-driven technologies within the Bittensor ecosystem, aligning treasury and operational goals. Strategic Vision Oblong's TAO treasury delivers value to investors through potential share price growth driven by strategic asset management, to TAO holders by enhancing Bittensor's ecosystem, and to the AI community by advancing decentralized innovation. As corporations increasingly adopt digital assets, Oblong leads by integrating AI and finance through TAO's unique role in Bittensor's growing network. Non-GAAP Financial Information Adjusted EBITDA is a non-GAAP financial measure. See 'GAAP to Non-GAAP Reconciliation' below for a reconciliation to net loss. About Oblong, Inc. Oblong (Nasdaq: OBLG) is building a robust cryptocurrency treasury focused on decentralized artificial intelligence (AI) and the acquisition of $TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. By championing open-source intelligence, Oblong offers unmatched opportunities for retail and institutional investors. Forward-looking and cautionary statements This press release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, that address activities that Oblong assumes, plans, expects, believes, intends, projects, estimates, or anticipates (and other similar expressions) will, should, or may occur in the future are forward-looking statements. Oblong's actual results may differ materially from its expectations, estimates, and projections, and consequently, you should not rely on these forward-looking statements as predictions of future events. Without limiting the generality of the foregoing, forward-looking statements contained in this press release include statements relating to the Company's plans to: i) deliver value through strategic treasury management and ii) explore partnerships to develop AI-driven technologies within the Bittensor ecosystem, aligning treasury and operational goals. The forward-looking statements are based on management's current belief, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties, including the volatility of market price for our securities, that may cause actual results in future periods to differ materially from such statements. A list and description of these and other risk factors can be found in the Company's Annual Report on Form 10-K for the year ending December 31, 2024, the Company's Form 10-Q filed on August 14, 2025 and in other filings made by the Company with the SEC from time to time. Any of these factors could cause Oblong's actual results and plans to differ materially from those in the forward-looking statements. Therefore, the Company can give no assurance that its future results will be as estimated. The Company does not intend to, and disclaims any obligation to, correct, update, or revise any information contained herein. December 31, 2024 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 10,795 $ 4,965 Digital assets 1,683 — Accounts receivable, net 15 186 Prepaid expenses and other current assets 566 118 Total current assets 13,059 5,269 Other assets 5 6 Total assets $ 13,064 $ 5,275 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable 122 105 Accrued expenses and other current liabilities 1,659 1,131 Deferred revenue 31 36 Total current liabilities 1,812 1,272 Total liabilities 1,812 1,272 Commitments and contingencies (see Note 9) Stockholders' equity: Preferred stock Series F, convertible; $0.0001 par value; $390,000 stated value; 5,000,000 shares authorized, 355 and 545 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively — — Common stock; $0.0001 par value; 150,000,000 shares authorized, 1,594,953 and 1,594,764 shares issued and outstanding as of June 30, 2025, respectively, and 1,144,926 and 1,144,737 shares issued and outstanding as of December 31, 2024, respectively — — Treasury Stock, 189 common shares (181 ) (181 ) Additional paid-in capital 244,984 236,458 Accumulated deficit (233,551 ) (232,274 ) Total stockholders' equity 11,252 4,003 Total liabilities and stockholders' equity $ 13,064 $ 5,275 Expand OBLONG, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ($ in thousands) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue $ 592 $ 611 $ 1,214 $ 1,237 Cost of revenue 364 491 737 1,120 Gross profit 228 120 477 117 Operating expenses: Research and development 3 65 6 115 Sales and marketing 6 57 14 111 General and administrative 902 1,016 1,831 2,093 Total operating expenses 911 1,138 1,851 2,319 Operating loss (683 ) (1,018 ) (1,374 ) (2,202 ) Interest income, net 47 44 73 92 Unrealized gain on digital assets 31 — 31 — Other income, net 78 44 104 92 Loss before income taxes (605 ) (974 ) (1,270 ) (2,110 ) Income tax expense — 9 7 9 Net loss $ (605 ) $ (983 ) $ (1,277 ) $ (2,119 ) Expand GAAP to Non-GAAP Reconciliation: Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net loss $ (605 ) $ (983 ) $ (1,277 ) $ (2,119 ) Other income, net (78 ) (44 ) (104 ) (92 ) Income tax expense — 9 7 9 Stock-based compensation — 31 - 62 Adjusted EBITDA loss $ (683 ) $ (987 ) $ (1,374 ) $ (2,140 ) Expand
Business Wire
a few seconds ago
- Business Wire
NETSCOUT Releases 2025 Environmental, Social, and Governance Report
WESTFORD, Mass.--(BUSINESS WIRE)-- NETSCOUT ® SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of observability, AIOps, cybersecurity, and DDoS attack protection solutions, today announced the publication of its FY2025 Environmental, Social, and Governance (ESG) Report. The report highlights NETSCOUT's progress against its four ESG pillars, including sustainability, lean but not mean company philosophy, community impact, and strengthening cybersecurity and compliance. NETSCOUT's strong governance is the foundation of the ESG program and reflects the company ethos of transparency, responsibility and a relentless drive towards making meaningful impacts. 'Our commitment to our employees, customers, shareholders, communities and the progress of our industry has been guided by a clear vision: to align our efforts with our corporate strategy in the service of long-term value creation,' said Jeff Levinson, Senior Vice President, General Counsel and Chief ESG Officer at NETSCOUT. 'Our sustainability accomplishments were significant and benefit our customers through sustainability by design innovations to reduce their energy consumption and operational costs.' The 2025 ESG Report includes voluntary disclosures of measurements aligned with relevant sector standards from the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-related Financial Disclosures (TCFD) framework. NETSCOUT's Environmental, Social, and Governance Report: Shares the near-term science-based emissions reduction targets for Scope 1, 2, and 3 Greenhouse Gas (GHG) emissions validated by the Science Based Targets initiative (SBTi), as well as metrics and trends. Demonstrates progress across each of NETSCOUT's four ESG focus areas and continued improvement against its ESG Maturity Model. Provides additional transparency into governance, including ESG oversight, corporate governance, and risk management. Celebrates 5,340 volunteer hours logged in support of over 300 non-profit organizations across the globe to make a positive difference in our local communities. Confirms reductions in greenhouse gas emissions and continued development of our measurement and assessment processes and tools. To learn more about NETSCOUT's commitment to ESG, the ESG maturity Model, and to review the complete ESG Report, visit NETSCOUT ESG, Sustainability, and Corporate Social Responsibility. About NETSCOUT NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through its unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world's largest enterprises, service providers, and public sector organizations. Learn more at or follow @NETSCOUT on LinkedIn, X, or Facebook. ©2025 NETSCOUT SYSTEMS, INC. All rights reserved. Third-party trademarks mentioned are the property of their respective owners.
